Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial (DREAMtherapy)

This study has been terminated.
(2 DLTs had been reported from first 4 patients on lowest possible dose cohort.)
Sponsor:
Collaborators:
Cancer Research UK
AstraZeneca
Information provided by (Responsible Party):
Suzanne Rowland, Christie Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01160926
First received: July 7, 2010
Last updated: January 26, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2016
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)